La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the pricing of an underwritten public offering of approximately 3.7 million shares of common stock, offered at a price of $33.50 per share, for gross proceeds of $125 million. In addition, La Jolla has granted the underwriters a 30-day option to purchase up to an additional 559,700 shares of common stock.